Table 2.
Diagnoses and biomarker availability.
| Data set | CN | MCI | AD | Sub-Total | MRI | CSF | Cognitive scores | |
|---|---|---|---|---|---|---|---|---|
| Training set | ADNI 1/GO/2 | 468 | 753 | 267 | 1488 | 100% | 72% | 100% |
| Test set | ADC | 125 | 80 | 129 | 334 | 100% | 83% | 99% |
| ARWiBo | 1399 | 169 | 152 | 1720 | 100% | 3% | 59% | |
| EDSD | 179 | 138 | 151 | 468 | 100% | 19% | 97% | |
| OASIS | 177 | 122 | 42 | 341 | 100% | NA | 100% | |
| PharmaCog | 0 | 147 | 0 | 147 | 100% | 99% | 100% | |
| ViTA | 41 | 15 | 2 | 58 | 100% | NA | 100% | |
| Total | 2389 | 1424 | 743 | 4556 | 100% | 36% | 77% |
The number of cognitively normal (CN), mild cognitive impairment (MCI), Alzheimer's disease (AD) and total subjects is reported for each data set. Biomarker availability is expressed as percentage related to the total subjects in each data set. No CSF biomarker is available for OASIS and ViTA data sets.